It is the consensus of the Haematology Reference Committee that this protocol is not considered best practice for this patient population.
Treatment schedule summary
Drug |
Dose |
Route |
Day |
iDArubicin |
12 mg/m2 |
IV |
1 to 3 |
Etoposide * |
75 mg/m2 |
IV infusion |
1 to 7 |
Cytarabine (Ara-C) |
100 mg/m2 |
CIV |
1 to 7 |
* Etopophos (etoposide phosphate) 113.6 mg is equivalent to etoposide 100 mg. Doses in this protocol are expressed as etoposide.
Cycles: 1 or 2. Usually given once but may be repeated if remission is not achieved
Notes:
The addition of etoposide has been shown to be beneficial in patients under the age of 55 in terms of response rate, however it also increases the risk of mucositis.1